ReviewJournal of evaluation in clinical practice2026
Emotional Blunting During Antidepressant Treatment: Implications for Clinical Decision-Making and Patient-Centred Care.
Review in Journal of evaluation in clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleEmotional blunting is frequently reported during antidepressant treatment but remains conceptually underdefined. Reduced emotional reactivity and affective intensity may represent therapeutic benefit, an adverse effect, residual depressive symptomatology, or a context-dependent combination of these possibilities. AIMS AND
objectivesTo clarify the phenomenology and clinical significance of antidepressant-associated emotional blunting, distinguish it from residual depression, anhedonia, and apathy, and consider its implications for long-term prescribing, shared decision-making, and patient-centred care.
methodEvidence from phenomenological and qualitative accounts, survey-based and clinical studies, neurobiological research, patient-reported outcome literature, and relevant ethical and clinical guidance was narratively integrated to examine the prevalence, mechanisms, subjective meanings, and management of emotional blunting.
resultsEmotional blunting is reported by a substantial proportion of antidepressant-treated patients, although estimates vary because of differences in definitions, instruments, populations, and study designs. Evidence suggests that serotonergic antidepressants may dampen the processing of both rewarding and aversive stimuli, but medication effects cannot always be clearly separated from residual illness. Patients' appraisals are heterogeneous: emotional attenuation may be experienced as protective or acceptable during acute treatment yet burdensome, alienating, or inconsistent with personal recovery during maintenance treatment. Misclassification may lead to inappropriate dose escalation, unnecessary continuation, or premature discontinuation. Clinical responses should therefore be individualised and may include maintaining treatment, dose reduction, switching, psychological or psychosocial interventions, or planned discontinuation.
conclusionEmotional blunting is best understood as a therapeutically ambivalent, patient-reported outcome whose significance varies with illness phase, treatment goals, perceived benefits, and individual values. Systematic enquiry and shared decision-making can support more clinically appropriate and person-centred antidepressant care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.